Abstract:
본 발명은 하기의 화학식 1로 표시되는 신규한 1-[1-(3,4-디알콕시페닐)-알킬]-1 H -피라졸 화합물 또는 그의 약제학적으로 허용 가능한 염, 이의 제조 방법 및 이를 유효성분으로 함유하는 것을 특징으로 하는 천식 및 만성폐쇄성 폐질환(Chronic Obstructive Pulmonary Disease)을 포함한 염증관련 질환의 치료 및 관절염, 아토피피부염, 백혈병과 각종 암 및 알쯔하이머 등의 퇴행성뇌질환의 예방 및 치료용 또는 기억력증진용 약제학적 조성물에 관한 것이다. [화학식 1]
Abstract:
An alkylcarbamoyl naphthalenyloxy methyloct N-hydroxyenamide derivative, its pharmaceutically acceptable salt, a method for preparing the derivative, and an anticancer pharmaceutical composition containing the derivative are provided to inhibit the enzymatic activity of histone deacetylase effectively and the proliferation of tumor cells. An alkylcarbamoyl naphthalenyloxy methyloct N-hydroxyenamide derivative is represented by the formula 1, wherein R1 is a C1-C3 alkyl group substituted or unsubstituted with at least one substituent selected from the group consisting of a C1-C3 alkyl group, a C1-C3 alkoxy group, a hydroxy C1-C3 alkyl group, a halophenyl group, a piperidinyl group, a morpholinyl group, a cyanomethyl group, a piperazinyl group, a di-C1-C3 alkylamino group, a di-C1-C3 alkylamino C1-C3 alkyl group, a piperidinyl C1-C3 alkyl group, a C1-C3 alkoxy C1-C3 alkyl group, a morpholino C1-C3 alkyl group, a piperazino C1-C3 alkyl group, a pyrrolidinyl group, an oxopyrrolidinyl group, a C1-C3 alkylpyrrolidinyl group, an imidazole group, an imidazolyl C1-C3 alkyl group and a thiophenyl group.
Abstract:
A novel compound is provided to show excellent activity on PDE-4 enzymes and high selectivity on other PDE enzymes, thereby being used as a therapeutic agent of inflammation related diseases, arthritis, atopic dermatitis, leukemia, various cancers and degenerative brain diseases with little side effects. A 1-[1-(3,4-dialkoxyphenyl)-alkyl]-1H-pyrazole compound is represented by a formula(1) and is prepared by reacting a halo-benzyl compound represented by a formula(2) with a pyrazole compound represented by a formula(3). In the formula(1), each R1 and R2 is independently H, linear or branched saturated or unsaturated C1-7 alkyl which may be substituted or unsubstituted by halogen, C3-7 cycloalkyl, (C3-7)cycloalkyl(C1-7)alkyl, aryl or heteroaryl, ar(C1-5)alkyl, or ar(C1-5)alkoxy, or the R1 and R2 may be linked to each other by C1-3 alkylene; each R3, R4 and R5 is independently H, phenyl, pyridinyl, N-oxypyridinyl, linear or branched saturated and unsaturated C1-7 alkyl, C3-7 cycloalkyl, (C3-10)cycloalkyl(C1-7)alkyl, halogen, cyano, nitro, amino, mono- or di(C1-7)alkylamino, mono or di(C1-7)alkylaminocarbonyl, C3-7 cycloalkylamino, 3 to 7-membered saturated or unsaturated hetero-ring including O, N or S, guanidinyl, ureido, benzyl, benzyloxy, formyl, C1-7 alkanoyl, C1-7 alkoxy, (C1-7)alkoxy(C1-7)alkyl, hydroxy(C1-7)alkyl, carboxyl, or (C1-7)alkoxycarbonyl; R6 is linear or branched saturated and unsaturated C1-7 alkyl, C3-7 cycloalkyl, (C3-10)cycloalkyl(C1-7)alkyl, phenyl, phenoxy, benzyl, benzyloxy, C1-7 alkoxy, or (C1-7)alkoxy(C1-7)alkyl. A pharmaceutical composition for treating or preventing diseases related to airway inflammation, arthritis, atopic dermatitis, leukemia, cancer or degenerative brain diseases comprises the 1-[1-(3,4-dialkoxyphenyl)-alkyl]-1H-pyrazole derivative as an effective ingredient.
Abstract:
1-[1-(3,4-Dialkoxyaryl)-pyridylmethyl]-1H-pyrazole compounds are provided to inhibit activity of PDE-4(phosphodiesterase-4) with high activity and selectivity without side effects, so that the compounds are useful for treating inflammation diseases, neurodegenerative disease and cancers. 1-[1-(3,4-Dialkoxyaryl)-pyridylmethyl]-1H-pyrazole compounds represented by the formula(1) are provided, wherein A is N or CH; R1 is linear or branched, saturated or unsaturated (C1-C7)alkyl or halogen-substituted linear or branched, saturated or unsaturated (C1-C7)alkyl; R2 is hydrogen atom, (C3-C7)cycloalkyl or (C3-C8)cycloalkylmethyl; R3, R4 and R5 are each independently hydrogen atom, phenyl, pyridinyl, N-oxypyridinyl, linear or branched, saturated or unsaturated (C1-C7)alkyl, (C3-C7)cycloalkyl, (C3-C10)cycloalkyl(C1-C7)alkyl, halogen atom, cyano, nitro, amino, mono- or di(C1-C7)alkylamino, mono- or di(C1-C7)alkylaminocarbonyl, (C3-C7)cycloalkylamino, 3- to 7-membered saturated or unsaturated hetero ring containing oxygen, nitrogen or sulfur in hetero ring, guanidinyl, ureido, benzyl, benzyloxy, formyl, (C1-C7)alkanoyl, (C1-C7)alkoxy, (C1-C7)alkoxy(C1-C7)alkyl, hydroxy(C1-C7)alkyl, carboxyl or (C1-C7)alkoxycarbonyl; and R6 is pyridinyl or N-oxypyridinyl group.
Abstract:
An alkylcarbamoyl naphthaleneoxypropenyl hydroxybenzamide derivative, its pharmaceutically acceptable salt, a method for preparing the derivative, and an anticancer pharmaceutical composition containing the derivative are provided to inhibit effectively the enzymatic activity of histone deacetylase and to suppress the proliferation of tumor cells. An alkylcarbamoyl naphthaleneoxypropenyl hydroxybenzamide derivative is represented by the formula 1, wherein R1 is H; and R2 is a C1-C6 alkyl group substituted or unsubstituted with at least one substituent selected from the group consisting of a di-C1-C3 alkylamino group, a pyrrolidinyl group, an oxopyrrolidinyl group, a methoxypyrrolidinyl group, a C1-C3 alkylpiperidinyl group, a morpholinyl group, an imidazolyl group, a methoxy group, an ethoxy group, a tetrahydroxyfuran group, a C3-C8 cycloalkenyl group, a furanyl group and a thiophenyl group, a C1-C6 alkyl group substituted with a fluorophenyl group, a di-C1-C3 alkylaminophenyl group or a methoxyphenyl group, a piperidine group substituted with a C1-C6 alkyl group, or a C3-C8 cycloalkyl group.
Abstract:
An alkylamino naphthalenyloxymethyl propenyl hydroxybenzamide derivative is provided to obtain a pharmaceutical composition having an anti-cancer effect by inhibiting activity of histone deacetylase, inducing differentiation of tumor cells and inhibiting growth of tumor cells. An alkylamino naphthalenyloxymethyl propenyl hydroxybenzamide derivative is represented by the following formula 1. In formula 1, R1 is H or a C1-C3 alkyl; R2 is a C1-C6 alkyl non-substituted or substituted with a substituent selected from the group consisting of di-C1-C3 alkylamino, C1-C4 alkylpyrrolidinyl, morpholinyl, imidazolyl, methoxy and thiophenyl, a C1-C6 alkyl substituted with hydroxyphenyl, di-C1-C3 alkylaminophenyl, methoxyphenyl or trifluoromethoxyphenyl, pyrrolidine non-substituted or substituted with C1-C3 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkyl C1-C3 alkyl, benzyl or C3-C8 cycloalkylcarbonyl, piperidine substituted with a C3-C8 cycloalkyl or C1-C6 alkyl, or a C3-C8 cycloalkyl, with the proviso that when R1 is H or CH3, R2 is not non-substituted C1-C2 alkyl and morpholinyl-substituted C1-C2 alkyl.
Abstract:
An alkylcarbamoyl naphthalenyloxy octenoyl hydroxyamide derivative, its pharmaceutically acceptable salt, a method for preparing the derivative, and an anticancer pharmaceutical composition containing the derivative or the salt are provided to inhibit the enzymatic activity of histone deacetylase effectively and to suppress the proliferation of tumor cells. An alkylcarbamoyl naphthalenyloxy octenoyl hydroxyamide derivative is represented by the formula 1, wherein R1 is a C1-C3 alkyl group substituted or unsubstituted with at least one substituent selected from the group consisting of a halophenyl group, a C1-C3 alkoxy C1-C3 alkyl group, a cyclohexanyl group, a furanyl group, a thiophenyl group, an imidazole group, an imidazolidyl C1-C3 alkyl group, a C1-C3 alkylamino group, a di-C1-C3 alkylamino group, a hydroxyphenyl group, a tetrahydrofuranyl group, a cyclohexyl group, a cyclohexenyl group, an oxopyrrolidinyl group, an alkoxyphenyl group, a di-C1-C3 alkylaminophenyl group, a C1-C3 alkylpyrrolidinyl group and a trifluoromethoxyphenyl group; a pyrrolidine group substituted or unsubstituted with at least one substituent selected from the group consisting of a C3-C8 cycloalkyl group, a C3-C8 cycloalkyl C1-C3 alkyl group, a benzyl group, a C1-C3 alkyl group or a C3-C8 cycloalkylcarbonyl group; a piperidine group substituted with a C1-C3 alkyl group or a C3-C8 cycloalkyl group; a furan group; or a C3-C8 cycloalkyl group.